[970] ERG Rearrangement Is Specific to Prostate Cancer and Does Not Occur in Any Other Common Epithelial Tumour

VJ Scheble, M Braun, C Ruiz, T Wilbertz, AC Stiedl, K Petersen, M Reischl, F Fend, G Kristiansen, L Bubendorf, M Rubin, S Perner. University Hospital of Tuebingen, Tuebingen, Germany; University Hospital Basel, Basel, Switzerland; University Hospital Zurich, Zurich, Switzerland; Weill Cornell Medical College, New York, NY; Research Center Karlsruhe, Karlsruhe, Germany

Background: The ERG rearrangement, a genetic alteration that is known from hematological diseases and Ewing's sarcoma, has recently been described in prostate cancer. With a frequency of 40 up to 78% reported in prostate resection material, it is the most common gene rearrangement in prostate cancer. The ERG rearrangement in prostate cancer might be an adjunct diagnostic marker in specific settings. The aim of this study was to assess, if the ERG rearrangement occurs in other common epithelial and non-epithelial tumors.
Design: We assessed 3033 tumor samples for their ERG rearrangement status using an ERG break-apart FISH assay. There were 2942 samples from common epithelial and non-epithelial tumors. We also evaluated 91 prostate cancer samples.
Results: Seventy-seven percent (2325) of the 3033 cases were assessable by FISH. We found ERG rearrangement in 24 of 63 (38%) prostate adenocarcinoma samples. Of note, none of the epithelial and non-epithelial tumors assessed revealed an ERG rearrangement. This included lung, colon, kidney, breast, endocrine, and hematopoietic malignancies among others.
Conclusions: We were able to confirm ERG rearrangement in approximately 40% of the prostate cancers tested. This is largest survey of non-prostate cancer tumors for the presence of ERG rearrangements. Although Ewing's sarcoma (EWS-ERG) and AML (FUS-ERG) have known rearrangements involving ERG, the current finding supports the hypothesis that ERG rearrangement is a highly prostate cancer specific alteration. This study does not exclude rearrangements of other ETS transcription factors in these other tumor types.
Category: Genitourinary (including renal tumors)

Tuesday, March 23, 2010 8:00 AM

Platform Session: Section A, Tuesday Morning


Close Window